jk - Obviously you are an expert. Gee I almost fell for it!
Thank god for posters like you.
This is why I love Yahoo message boards. Guys like you can act like big shots.
Synergy Pharma rated New Buy at Rodman
Oct 1 2015, 07:50 ET | By: Eli Hoffmann, SA News Editor Contact this editor with comments or a news tip
Price-target $20 (implied upside 279%)."Synergy represents a late-stage, highly risk-mitigated and undervalued name in the biotech sector, as its lead candidate plecanatide has already completed two pivotal Phase 3 trials in chronic idiopathic constipation (CIC) successfully and is slated to be filed for approval by the end of this year.""From our perspective, Synergy possesses potentially the most favorably-positioned drug in disorders of the lower GI tract."Firm notes that Ironwood (NASDAQ:IRWD), the originator of linaclotide, trades at a $1.5B valuation, a substantial premium to the $600M market cap of Synergy, even though Ironwood does not own the full rights to its product, while Synergy retains 100% ownership of plecanatide. The two products seem to have equal efficacy, but linaclotide seems to induce a higher discontinuation rate.Over the past week, BTIG put a $11 target on SGYP, and Canaccord a $19 target.Related: Does Synergy Pharma's Plecanatide Blow Away The Competition? (Jul. 16)Related: Synergy Pharma Still Has Significant Upside Potential (Jul. 8)
I love how people come on message boards and act like they know it all.
If we knew it all we wouldn't be wasting our time posting nonsense on a Yahoo message board, would we?
SGYP appears by all accounts to have a great drug.
That's enough for a retail pissant like myself.
If you haven't noticed biotech is getting crushed and little ol Synergy doesn't have a drug approved yet. IRWD is like 40% off it's highs and you are like a total nincompooper.
Easy money? Anyone that recommended that post is naive. Nothing is guaranteed. There are a lot of posters here that were sure the company would be bought out by now.
"...a "spin off" of dolcanatide is highly highly unlikely."
I totally agree.
I'm assuming you haven't owned Synergy a long time.
Here's some Synergy history for you:
Back in Febuary 2014 Synergy spun off FV-100 assets into a newly formed subsidiary, ContraVir Pharmecuticals. There was a 100% distribution of the ContraVir shares of common stock, held by
Synergy, to Synergy's stockholders on a pro-rata basis.
It's Sept 1st. Trials often take longer than anticipated to fully enroll. I wouldn't get too nervous yet but I'm not you. The CIC Phase 3 results were later than most here predicted.
From ClinicalTrials.gov (last updated June 2015):
Estimated Enrollment: 1050
Study Start Date: December 2014
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: November 2015 (Final data collection date for primary outcome
The study completion date is Dec 2015. The company has said the topline data will be forthcoming late 2015/ early 2016. I have no reason to doubt them.
"China has unleashed an unprecedented package of support measures, including using state-backed entities to buy stocks and cracking down on "malicious" short-selling -- when investors sell shares they do not own in anticipation of a fall in their price."
Analyst Timothy Chiang said, "We think SGYP’s plecanatide shows promise as a future treatment for CIC and IBS-C, which is a growing market category in the US. With ~45 million Americans suffering from chronic constipation and IBS, and companies like Allergan (AGN, Not Rated) and Valeant (VRX, Buy, $290 PT) focusing their marketing efforts on GI treatments, it seems logical to imagine SGYP as a takeover candidate."
It's no excuse for my stupid post this morning but one of my stocks is green today. EXEL is up over 6%. I'm not telling anyone to buy it - I have no idea why it's going up.
Sorry about the really bad post.
Sorry about that. I looked at two of my bios before posting. One wasn't trading and the other was green.
It was obviously a stupid post on my part.
If someone would've sold their stock and we're looking to repurchase, I would think they might want to wait till either the stock goes down to like 5.50 (possible if the market continues to tank) or wait till around November to start buying. The IBS-C results aren't due till the end of this year or early next year and (baring a partnership or buyout) the stock the stock might not go up significantly till then.
The Food and Drug Administration Amendments Act requires sponsors of applicable clinical trials to report findings to ClinicalTrials.gov within one year of completion. I don't believe there are requirements to publicly disclose trial results.
The top line results are the primary end points of the trial. More complete disclosure of trial results including secondary end points and additional analysis of the data are often presented at conferences and published in medical journals.
I have no idea what "internal results" refers to.
A few biotech stocks managed to buck the trend today, but most of them still finished down for the week.
"We're pinned at $7 for options expiration..."
Kindly correct me if I'm wrong but isn't the August maximum pain for this stock 8?
Why would the stock be "pinned" at 7 when the max pain is 8?